Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BRAF mutations in papillary thyroid carcinoma.

Katarzyna Wojciechowska1, Andrzej Lewinski

  • 1Department of Endocrinology and Metabolic Diseases, The Medical University of Lodz, Polish Mother's Memorial Hospital - Research Institute in Lodz, Lodz, Poland.

Endocrine Regulations
|January 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic architecture of patients with autism spectrum disorder - data analysis based on the literature review.

BMC medical genomics·2026
Same author

Diversity of molecular karyotypes of 234 pediatric patients with autism spectrum disorder in chromosomal microarray analysis.

BMC psychiatry·2026
Same author

<i>Psidium cattleyanum</i> Sabine as a Source of Bioactive Compounds for Skin Disorders.

Molecules (Basel, Switzerland)·2026
Same author

The Skin Microbiome and Bioactive Compounds: Mechanisms of Modulation, Dysbiosis, and Dermatological Implications.

Molecules (Basel, Switzerland)·2025
Same author

GLObal Solar Wind Structure (GLOWS).

Space science reviews·2025
Same author

Prevention of fatty acid-induced maladaptation in secretin tumor cell-1 enteroendocrine cells by allicin, a transient receptor potential ankyrin 1 agonist.

The Journal of pharmacology and experimental therapeutics·2025

The BRAF gene mutation is a key characteristic of papillary thyroid carcinoma (PTC) and other cancers. This mutation may serve as a valuable diagnostic and prognostic marker for PTC, potentially improving treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy originating from thyroid follicular cells.
  • Current markers like RET, TRK, and MET mutations lack correlation with PTC clinicopathological features, necessitating new markers.
  • The BRAF oncogene mutation is frequently observed in PTC and related cancers, including melanoma, colon cancer, gliomas, and lung cancer.

Purpose of the Study:

  • To investigate the role of BRAF gene mutations as potential diagnostic and prognostic markers in papillary thyroid carcinoma.
  • To explore the correlation between BRAF mutations and clinicopathological features of PTC.
  • To assess the potential of BRAF inhibitors in the therapeutic management of thyroid cancer.

Main Methods:

Related Experiment Videos

  • Analysis of BRAF gene mutations in PTC samples.
  • Correlation studies between BRAF mutation status and clinical stage.
  • Review of existing literature on BRAF mutations in various cancers and potential therapeutic implications.

    • Main Results:

    • BRAF gene mutation, particularly the V600E variant, is characteristic of PTC and poorly differentiated/undifferentiated thyroid cancers.
    • BRAF mutation leads to hyperactivation of the RAS/RAF/MEK/MAPK pathway, promoting uncontrolled cell proliferation.
    • Preliminary data suggest a correlation between BRAF mutation and PTC clinical stage, indicating its potential as a diagnostic and prognostic marker.

    Conclusions:

    • The BRAF gene mutation is a significant molecular event in papillary thyroid carcinoma.
    • BRAF mutation status may serve as a valuable diagnostic and prognostic marker for PTC.
    • Targeted therapies involving BRAF inhibitors show promise for improving thyroid cancer treatment outcomes.